drugset / Trial / NCT01125930

Atralin Gel for the Treatment of Rosacea

NCT01125930

Phase 3 Terminated 68 enrolled Lisa E. Maier Bausch Health Americas, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR).

Timeline

Start
2010-05
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tretinoin Small molecule 0.05 % Topical

Indications